You searched for: grajjiet (Maltesiska - Engelska)

grajjiet avversi fit-testijiet tal-laboratorju
laboratory adverse events

dawn il- grajjiet huma ta ’ spiss transitorji.
these events are often transitory.

ta ’ ≥ 1%), jew ikkunsidrati klinikament rilevanti (għal grajjiet ta ’ < 1%)
statistically significantly greater than the corresponding placebo rate (for events ≥ 1%) or considered ro

minbarra dan, l-awtoritajiet kompetenti fl-istati membri jistgħu fuq bażi tempestiva jirrapportaw dwar grajjiet speċifiċi ta' sinifikat partikolari.
in addition, the competent authorities in member states may on a timely basis report on specific events of particular significance.

aw grajjiet avversi fit- testijiet tal- laboratorju zimulti ma ntweriex li effetwa ir- riżultati tat- testiijiet tal- laboratorju.
laboratory adverse events zimulti has not been shown to alter laboratory test values.

f’ każ li l- kontroll tal- glucose mhux tajjeb jew hemm tendenza għall- iżvilupp ta ’ grajjiet ta ’ iper - jew ipo- glicemija, għandhom jiġu investigati jekk il- pazjent huwiex qed iżomm mad- dieta preskritta, s- siti ta ’ l- injezzjoni, t- teknika korretta ta ’ l- injezzjoni u l- fatturi rilevanti l- ohrajn kollha qabel ma l - aġġustament fid- doża tkun ikkunsidrata
145 in case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.